Skip to main content
Premium Trial:

Request an Annual Quote

BD Reports Strong Fiscal Q4 Revenue Growth; Shares Climb 9 Percent

NEW YORK, Nov. 3 (GenomeWeb News) - Becton Dickinson reported today 10 percent revenue growth in its fiscal fourth quarter, and a positive outlook for the next year. However, 7 percent of that growth was organic while the remaining 3 percent was due to favorable currency exchange rates.

 

Total revenue for the three months ended Sept. 30 increased to $1.4 billion from $1.2 billion year over year. Of the three segments, BD Medical accounted for slightly more than half of total revenues, at 55 percent. BD Medical's total fourth-quarter revenues increased 11 percent to $762 million.

 

The BD Diagnostics segment saw its total revenues for the quarter increase 8 percent to $403 million. Growth in this segment was spurred by strong international sales, which outperformed the United States.

 

In the BD Biosciences segment, total quarterly revenue increased 12 percent to $214 million. Research instrument and reagent sales continued to be primary growth contributors, the company said.

 

Geographically, U.S. revenues increased 9 percent to $687 million over the previous quarter, and international revenues increased 11 percent to $692 million. All business segments gained from favorable exchange rates and the company estimated a 3-percent benefit from foreign currency translation for the quarter, the company said.

 

R&D spending for the fourth quarter increased 30 percent to $76.5 million from $58 million.

 

"Performance such as this will allow us to increase the pace of our R&D spending while also targeting double-digit earnings growth," Edward J. Ludwig, BD's president and CEO said in a statement.

 

BD also posted a profit of approximately $149 million, or $.60 per share, from approximately $67 million, or $.27 per share during last year's fourth quarter. BD expects "earnings will grow by approximately 10 percent" for fiscal year 2006, said Ludwig.

 

The company did not break out its cash on hand.

 

Shares in BD were up 8.8 percent, or $4.53, at $56.28 in mid-afternoon trading.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.